Evolus, Inc. (EOLS) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Evolus reported strong financial performance with a 25% YoY revenue increase and improved gross margins. Net income turned positive, reflecting effective cost management. Despite no mention of dividends or buybacks, the solid growth figures and profitability improvements are positive indicators. The absence of negative Q&A feedback further supports a positive sentiment. However, lack of market cap data limits precise prediction.
Key Financial Performance
Revenue Evolus reported $200 million in revenue for Q4 2025, a 25% increase year-over-year, driven by strong sales in the U.S. and international markets.
Gross Margin The gross margin for Q4 2025 was 68%, up from 65% in Q4 2024, attributed to improved operational efficiencies and cost management.
Net Income Net income for Q4 2025 was $15 million, compared to a net loss of $5 million in Q4 2024, due to increased revenue and better expense control.
Operating Expenses Operating expenses were $120 million in Q4 2025, a 10% increase year-over-year, primarily due to higher marketing and R&D investments.
Cash Flow Cash flow from operations was $30 million in Q4 2025, up from $20 million in Q4 2024, reflecting improved profitability and working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-Looking Statements: The company acknowledges that actual results may differ materially due to risks and uncertainties outlined in their earnings press release and SEC filings. These forward-looking statements are based on current assumptions, and the company undertakes no obligation to update them.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Forward-looking statements: Today's call will include forward-looking statements. Actual results may differ materially due to risks and uncertainties outlined in our earnings press release and SEC filings. These forward-looking statements are based on current assumptions, and we undertake no obligation to update them.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Program: No specific mention of a dividend program was made during the call.
Shares Buyback Program: No specific mention of a shares buyback program was made during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Alyssa Larios
Annabel Samimy
BTIG LLC
CEO Director
Communications Moatazedi
Communications Today
Development Annabel
Dietschi BNP
Director Tatjana
Division Alyssa
Division Douglas
Division Ear
Division Navann
Division PM
Douglas Tsao
EST afternoon
Evolus Full
Full Conference
Instructions
LLC Research
Larios Leerink
Mitchell Chief
Nareg Sagherian
Navann Ty
Officer Rui
PM EST
Paribas Research
Research Division
Rui Avelar
Sam Eiber
Tatjana Mitchell
Tsao HC
Ty Dietschi
Wainwright Co
obligation non
EOLS Transcript
Evolus, Inc. (EOLS) Q1 2026 Earnings Call Transcript
Positive5-5
The earnings call summary and Q&A reveal several positive indicators, such as strong international growth, effective bundling strategies, and stable market sentiment despite competition. The company maintains healthy margins and anticipates FDA approval for new products. While some responses lacked specificity, the overall sentiment is optimistic, with guidance aligning with consensus estimates and expected growth in key markets. These factors suggest a likely positive stock price movement over the next two weeks.
Evolus, Inc. (EOLS) Q4 2025 Earnings Call Transcript
Positive3-4
Evolus reported strong financial performance with a 25% YoY revenue increase and improved gross margins. Net income turned positive, reflecting effective cost management. Despite no mention of dividends or buybacks, the solid growth figures and profitability improvements are positive indicators. The absence of negative Q&A feedback further supports a positive sentiment. However, lack of market cap data limits precise prediction.
Evolus, Inc. (EOLS) Q3 2025 Earnings Call Transcript
Positive11-8
The earnings call and Q&A reflect a positive outlook, with strong product adoption, strategic cost optimization, and promising guidance for Q4. Despite some headwinds, the company anticipates a strong Q4, supported by effective marketing strategies and expected seasonal demand. The positive sentiment is further bolstered by the focus on expanding training for Evolysse, strategic bundling with Jeuveau, and the potential for long-term revenue growth. However, the lack of specific guidance on tariffs and sales splits introduces some uncertainty, warranting a cautious but optimistic rating.
Evolus, Inc. (EOLS) Q2 2025 Earnings Call Transcript
Unknown8-5
The earnings call summary indicates mixed signals: strong market share growth and product launches are positive, but macroeconomic factors and reduced consumer demand are concerning. The Q&A reveals uncertainties, such as the impact of promotions and consumer sentiment. Despite positive long-term targets and a strong product launch, the immediate outlook is tempered by economic challenges and cautious guidance adjustments. Without a clear market cap, it's challenging to predict a strong movement, hence a neutral rating is appropriate.
EOLS Slides
EOLS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
